Embolism Diagnostic Market: 2017 Global Industry Trends 2021 Embolism Diagnostic Industry Global Market | Page 2

Pulmonary Embolism Diagnostic Market - Global Industry Analysis, Size,
Share, Growth, Trends and Forecasts 2017 – 2021
Pulmonary Embolism Diagnostics Market is anticipated to increase at a significant CAGR during the years
2017-2021. The pulmonary embolism diagnostic market is expected to increase due to growth in number of
cancer patients, aging population, increase in per-capita healthcare expenditure, etc. Yet the market faces
some challenges such as, prohibition of Technegas (an agent of V/Q Scan) in the US and introduction of
Novel Oral anticoagulants.
Company Coverage: Cyclopharm, Jubilant LifeSciences Limited, Philips, Siemens.
Pulmonary embolism is a condition where the clot that is formed deep into the veins of the patient legs (or
in any other body part) breaks off and travels through the bloodstream to the lungs. The clot has a
tendency to block a blood vessel in the lungs and hence damage them.
Pulmonary embolism is not a disease rather it is a complication of underlying VTE. There are several risk
factors for pulmonary embolism such as cancer, obesity, sedentary lifestyle, age factor, major surgery,
genetic blood clotting disorder or fracture of the hip or leg, etc. The onset of pulmonary embolism is
depicted by shortness of breath, sudden chest pain and coughing blood.
There are different types of tests done to detect pulmonary embolism, however, Computed Tomography
Pulmonary Angiogram (CTPA) is the gold standard for detecting pulmonary embolism. Another alternative
test done to detect pulmonary embolism is Ventilation-Perfusion (V/Q) Scanning.
Complete report available at http://www.marketreportsonline.com/585820.html